Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. Puglisi F, Gerratana L, Lambertini M, Ceppi M, et al. NPJ Breast Cancer 2021;7:82.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Puglisi F, Gerratana L, Lambertini M, Ceppi M, et al. Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. NPJ Breast Cancer 2021;7:82.
PMID: 34183674